Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat. 1991

F B Jolicoeur, and R Rivest, and A Drumheller
Department of Psychiatry, Faculty of Medicine, University of Sherbrooke, Quebec, Canada.

Bilateral administration of 6-hydroxydopamine in the medial fore-brain bundle at the level of the posterolateral hypothalamus in rats resulted in hypokinesia, muscular rigidity and tremor as determined by various behavioral assessment procedures. These neurological signs were accompanied by marked decreases in the concentrations of dopamine and its main metabolites dihydroxyphenylacetic acid and homovanillic acid in both striatum and nucleus accumbens. Administration of apomorphine (1 mg/kg) or L-Dopa (60 mg/kg) reversed or totally abolished the hypokinesia, rigidity and tremor in lesioned animals. Together, the present findings demonstrate that bilateral intrahypothalamic administration of 6-OHDA results in the appearance of the three cardinal symptoms of Parkinson's disease in rats. This model should prove to be valuable for both the study of the neuropathological processes underlying the neurological signs of this disease and the screening of potential antiparkinson agents.

UI MeSH Term Description Entries
D007034 Hypothalamus, Posterior The part of the hypothalamus posterior to the middle region consisting of several nuclei including the medial maxillary nucleus, lateral mammillary nucleus, and posterior hypothalamic nucleus (posterior hypothalamic area). The posterior hypothalamic area is concerned with control of sympathetic responses and is sensitive to conditions of decreasing temperature and controls the mechanisms for the conservation and increased production of heat. Hypothalamic Region, Posterior,Posterior Hypothalamic Region,Area Hypothalamica Posterior,Hypothalamus Posterior,Mammillary Region,Posterior Hypothalamus,Posterior Periventricular Nucleus,Premammillary Nucleus,Supramammillary Commissure,Supramammillary Nucleus,Area Hypothalamica Posteriors,Commissure, Supramammillary,Commissures, Supramammillary,Hypothalamic Regions, Posterior,Hypothalamica Posterior, Area,Hypothalamica Posteriors, Area,Hypothalamus Posteriors,Mammillary Regions,Nucleus, Posterior Periventricular,Nucleus, Premammillary,Nucleus, Supramammillary,Periventricular Nucleus, Posterior,Posterior Hypothalamic Regions,Posterior, Area Hypothalamica,Posterior, Hypothalamus,Posteriors, Area Hypothalamica,Posteriors, Hypothalamus,Region, Mammillary,Region, Posterior Hypothalamic,Regions, Mammillary,Regions, Posterior Hypothalamic,Supramammillary Commissures
D008297 Male Males
D009127 Muscle Rigidity Continuous involuntary sustained muscle contraction which is often a manifestation of BASAL GANGLIA DISEASES. When an affected muscle is passively stretched, the degree of resistance remains constant regardless of the rate at which the muscle is stretched. This feature helps to distinguish rigidity from MUSCLE SPASTICITY. (From Adams et al., Principles of Neurology, 6th ed, p73) Cogwheel Rigidity,Extrapyramidal Rigidity,Gegenhalten,Nuchal Rigidity,Rigidity, Muscular,Catatonic Rigidity,Extensor Rigidity,Cogwheel Rigidities,Gegenhaltens,Muscular Rigidity,Rigidities, Cogwheel,Rigidity, Catatonic,Rigidity, Cogwheel,Rigidity, Extensor,Rigidity, Extrapyramidal,Rigidity, Muscle,Rigidity, Nuchal
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D006719 Homovanillic Acid A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid. 3-Methoxy-4-Hydroxyphenylacetic Acid,4-Hydroxy-3-Methoxyphenylacetic Acid,3 Methoxy 4 Hydroxyphenylacetic Acid,4 Hydroxy 3 Methoxyphenylacetic Acid,Acid, 3-Methoxy-4-Hydroxyphenylacetic,Acid, 4-Hydroxy-3-Methoxyphenylacetic,Acid, Homovanillic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006892 Hydroxydopamines Dopamines with a hydroxy group substituted in one or more positions. Hydroxydopamine

Related Publications

F B Jolicoeur, and R Rivest, and A Drumheller
September 1987, Neuropharmacology,
F B Jolicoeur, and R Rivest, and A Drumheller
June 1979, Pharmacology, biochemistry, and behavior,
F B Jolicoeur, and R Rivest, and A Drumheller
January 1963, Acta neurologica Scandinavica. Supplementum,
F B Jolicoeur, and R Rivest, and A Drumheller
January 1978, Pharmacology, biochemistry, and behavior,
F B Jolicoeur, and R Rivest, and A Drumheller
May 1985, Behavioural brain research,
F B Jolicoeur, and R Rivest, and A Drumheller
January 2016, Journal of Asian natural products research,
F B Jolicoeur, and R Rivest, and A Drumheller
August 1998, Neuroreport,
F B Jolicoeur, and R Rivest, and A Drumheller
January 2002, Life sciences,
F B Jolicoeur, and R Rivest, and A Drumheller
January 1989, Journal of neural transmission,
F B Jolicoeur, and R Rivest, and A Drumheller
August 1970, The American journal of physiology,
Copied contents to your clipboard!